| Class | 15-PGDH inhibitor |
|---|---|
| Cas number | 2927452-83-1 |
| Pubchem | 169836897 |
| Chemspiderid | 133325048 |
| Iupac name | 7-[(1aS,7bR)-6-(4,4-difluoropiperidine-1-carbonyl)-1,1a,2,7b-tetrahydro-3H-cyclopropa[c][1,8]naphthyridin-3-yl]-2-methyl[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one |
| C | 22 |
| H | 22 |
| F | 2 |
| N | 6 |
| O | 2 |
| Smiles | O=C1N2C=CC(=CC2=NN1C)N1C[C@H]2C[C@H]2c2cc(cnc12)C(=O)N1CCC(F)(F)CC1 |
| Stdinchi | 1S/C22H22F2N6O2/c1-27-21(32)29-5-2-15(10-18(29)26-27)30-12-14-9-16(14)17-8-13(11-25-19(17)30)20(31)28-6-3-22(23,24)4-7-28/h2,5,8,10-11,14,16H,3-4,6-7,9,12H2,1H3/t14-,16-/m1/s1 |
| Stdinchikey | KDAKIHHOWNCOTC-GDBMZVCRSA-N |
HW201877 is a drug which acts as a potent inhibitor of the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH). It increases levels of prostaglandin E2 and stimulates tissue regeneration, and has been researched in animal studies for treatment of conditions such as inflammatory bowel disease and idiopathic pulmonary fibrosis.[1]
References
- ^ Li Q, Zang Y, An D, Yin S, Wu H, Wang M, Li C, Zhou Y, Liu L, Zhang X (July 2025). "Discovery of HW201877: A Highly Potent and Orally Bioavailable Inhibitor of 15-Prostaglandin Dehydrogenase to Potentiate Tissue Repair and Regeneration". Journal of Medicinal Chemistry. 68 (13): 14099–14113. doi:10.1021/acs.jmedchem.5c01361. PMID 40568827